Dr Ahsen Özcan
Ahsen obtained her PhD in microbiology from LMU Munich / Max Planck Institute for Terrestrial Microbiology in July 2019. During her PhD study, she characterized the ‘’putative” type IV CRISPR-Cas system. Afterwards, she worked as a postdoctoral fellow at the Massachusetts Institute of Technology (AbuGoot Lab) and characterized single effector RNA targeting CRISPR-Cas system (Cas7-11). After a brief stint as a CRISPR-Cas senior researcher with The Scientific and Technological Research Council of Turkey (TÜBITAK), she joined HIRI and the Beisel lab in 2021. Her current research and passion focus on developing CRISPR-based tools for diagnosis.